As a bioentrepreneur in the highest stakes arena of any industry, if you are treating your innovation’s path to market with antiquated methods, you miss out on an advantage over your competition. Read More
As 2018 drew to an end a notable lack of merger and acquisition activity among biopharma companies was probably one of the biggest grumbles heard about the sector. Read the full report. Read More
https://massbiotechboom.com Read More
In the 2019 edition of our Life Sciences and Health Care Horizons publication, our global team identifies a number of current and evolving trends that are shaping the future of the industry. Read More
The Vantage 2018 in Review report paints a mixed picture for biopharma and medtech in 2018. Read More
The biotech “cluster” of East Cambridge has long been credited with supporting an industry collaboration and knowledge sharing environment not seen on this scale anywhere else, but where is the money Read More
Our global Life Sciences and Health Care team reports on current and evolving trends that are shaping the future of the industry. Read More
Every complex discovery program can face a unique set of challenges. Read More
As Massachusetts’s current 10-year, $1 billion life science program sunsets in 2018, Governor Baker plans to add an additional $500 million in life science program funding. Read More
In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital Read More
